ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Up 6.7% After Adult Ryoncil Data Readout Validates Earlier Second-Line Use
In February 2026, Mesoblast reported data from patients treated under the U.S. Emergency Investigational New Drug program showing that its FDA-approved cell therapy Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease across children and adults, at different treatment lines and regardless of ruxolitinib use or resistance.
The findings, which highlighted better completion of treatment and survival when Ryoncil was used...